Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 114

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Gene variant effects across sodium channelopathies predict function and guide precision therapy

Brunklaus, Andreas, Feng, Tony, Brünger, Tobias, Perez-Palma, Eduardo, Heyne, Henrike, Matthews, Emma, Semsarian, Christopher, Symonds, Joseph D, Zuberi, Sameer M, Lal, Dennis, Schorge, Stephanie·2022·Brain
DOI 10.1093/brain/awac006PMC PMC9897196
Open this paper in CoChat — free account

Abstract

Pathogenic variants in the voltage-gated sodium channel gene family lead to early onset epilepsies, neurodevelopmental disorders, skeletal muscle channelopathies, peripheral neuropathies and cardiac arrhythmias. Disease-associated variants have diverse functional effects ranging from complete loss-of-function to marked gain-of-function. Therapeutic strategy is likely to depend on functional effect. Experimental studies offer important insights into channel function but are resource intensive and only performed in a minority of cases. Given the evolutionarily conserved nature of the sodium channel genes, we investigated whether similarities in biophysical properties between different voltage-gated sodium channels can predict function and inform precision treatment across sodium channelopathies. We performed a systematic literature search identifying functionally assessed variants in any of the nine voltage-gated sodium channel genes until 28 April 2021. We included missense variants that had been electrophysiologically characterized in mammalian cells in whole-cell patch-clamp recordings. We performed an alignment of linear protein sequences of all sodium channel genes and correlated variants by their overall functional effect on biophysical properties. Of 951 identified records, 437 sodium channel-variants met our inclusion criteria and were reviewed for functional properties. Of these, 141 variants were epilepsy-associated (SCN1/2/3/8A), 79 had a neuromuscular phenotype (SCN4/9/10/11A), 149 were associated with a cardiac phenotype (SCN5/10A) and 68 (16%) were considered benign. We detected 38 missense variant pairs with an identical disease-associated variant in a different sodium channel gene. Thirty-five out of 38 of those pairs resulted in similar functional consequences, indicating up to 92% biophysical agreement between corresponding sodium channel variants (odds ratio = 11.3; 95% confidence interval = 2.8 to 66.9; P < 0.001). Pathogenic missense variants were clustered in specific functional domains, whereas population variants were significantly more frequent across non-conserved domains (odds ratio = 18.6; 95% confidence interval = 10.9–34.4; P < 0.001). Pore-loop regions were frequently associated with loss-of-function variants, whereas inactivation sites were associated with gain-of-function (odds ratio = 42.1, 95% confidence interval = 14.5–122.4; P < 0.001), whilst variants occurring in voltage-sensing regions comprised a range of gain- and loss-of-function effects. Our findings suggest that biophysical characterisation of variants in one SCN-gene can predict channel function across different SCN-genes where experimental data are not available. The collected data represent the first gain- versus loss-of-function topological map of SCN proteins indicating shared patterns of biophysical effects aiding variant analysis and guiding precision therapy. We integrated our findings into a free online webtool to facilitate functional sodium channel gene variant interpretation (http://SCN-viewer.broadinstitute.org).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awac006

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SCN protein structure and position of disease-causing missense versus gnomAD variants. (A) and (B) SCN protein structure from side and top view. (C) Patient variants shown in red. (D) GnomAD variants shown in blue.
Figure 1 SCN protein structure and position of disease-causing missense versus gnomAD variants. (A) and (B) SCN protein structure from side and top view. (C) Patient variants shown in red. (D) GnomAD variants shown in blue.CC BY-NC · PubMed Central
Figure 2 Enrichment analysis of gnomAD versus pathogenic variants and LoF versus GoF variants. Enrichment analysis of (A) gnomAD versus pathogenic and (B) LoF versus GoF variants across different protein parts including four homologous domains (D1–D4), each consisting of six transmembrane segments (S1–S6) and large cytoplasmic loops.
Figure 2 Enrichment analysis of gnomAD versus pathogenic variants and LoF versus GoF variants. Enrichment analysis of (A) gnomAD versus pathogenic and (B) LoF versus GoF variants across different protein parts including four homologous domains (D1–D4), each consisting of six transmembrane segments (S1–S6) and large cytoplasmic loops.CC BY-NC · PubMed Central
Figure 3 2D representation of pathogenic SCN variants with functional effects. 2D representation of the SCN protein. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and S5–6 the pore region. Individual missense variants are displayed as different coloured bars. Blue denotes GoF, red LoF and yellow mixed function. Analogue missense pairs are displayed as circles with amino acid details.
Figure 3 2D representation of pathogenic SCN variants with functional effects. 2D representation of the SCN protein. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and S5–6 the pore region. Individual missense variants are displayed as different coloured bars. Blue denotes GoF, red LoF and yellow mixed function. Analogue missense pairs are displayed as circles with amino acid details.CC BY-NC · PubMed Central
Figure 4 3D illustration comparing GoF with LoF locations across the SCN protein. (A) GoF variants are illustrated in blue. (B) LoF variants are illustrated in red.
Figure 4 3D illustration comparing GoF with LoF locations across the SCN protein. (A) GoF variants are illustrated in blue. (B) LoF variants are illustrated in red.CC BY-NC · PubMed Central
Figure 5 In-silico prediction versus reported biophysical SCN variant effects. Prediction agreement [as a percentage (%)] detailed according to different protein parts including four homologous domains (D1–D4), each consisting of six transmembrane segments (S1–S6) and large cytoplasmic loops. In silico prediction was performed according to ‘funNCion’ (http://funNCion.broadinstitute.org).
Figure 5 In-silico prediction versus reported biophysical SCN variant effects. Prediction agreement [as a percentage (%)] detailed according to different protein parts including four homologous domains (D1–D4), each consisting of six transmembrane segments (S1–S6) and large cytoplasmic loops. In silico prediction was performed according to ‘funNCion’ (http://funNCion.broadinstitute.org).CC BY-NC · PubMed Central
Figure 6 2D representation of SCN variants with functional effects according to single sodium channels. 2D representation of different SCN proteins. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and segments S5–6 the pore region. Individual missense variants are displayed as different coloured circles. Blue denotes GoF, red LoF, yellow mixed function and purple similar-to-wild-type (STW). Benign variants are illustrated in pale colours.
Figure 6 2D representation of SCN variants with functional effects according to single sodium channels. 2D representation of different SCN proteins. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and segments S5–6 the pore region. Individual missense variants are displayed as different coloured circles. Blue denotes GoF, red LoF, yellow mixed function and purple similar-to-wild-type (STW). Benign variants are illustrated in pale colours.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 73

  1. Goldin, 2000, Nomenclature of voltage-gated sodium channels, Neuron, 28, 365, 10.1016/S0896-6273(00)00116-1 · DOI
  2. Hodgkin, 1952, A quantitative description of membrane current and its application to conduction and excitation in nerve, J Physiol, 117, 500, 10.1113/jphysiol.1952.sp004764 · DOI · Paper page
  3. Spillane, 2016, Genetic neurological channelopathies: molecular genetics and clinical phenotypes, J Neurol Neurosurg Psychiatry, 87, 37
  4. Brunklaus, 2014, Genotype phenotype associations across the voltage-gated sodium channel family, J Med Genet, 51, 650, 10.1136/jmedgenet-2014-102608 · DOI · Paper page
  5. Catterall, 2005, International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels, Pharmacol Rev, 57, 397, 10.1124/pr.57.4.4 · DOI
  6. Yu, 2004, The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis, Sci STKE, 2004, re15, 10.1126/stke.2532004re15 · DOI
  7. Brunklaus, 2020, Precision medicine in sodium channelopathies - Moving beyond seizure control towards disease modification, Eur J Paediatr Neurol, 24, 7, 10.1016/j.ejpn.2020.01.008 · DOI
  8. Mantegazza, 2019, SCN1A/NaV1.1 channelopathies: Mechanisms in expression systems, animal models, and human iPSC models, Epilepsia, 60, S25, 10.1111/epi.14700 · DOI
  9. Cestèle, 2008, Self-limited hyperexcitability: Functional effect of a familial hemiplegic migraine mutation of the Nav1.1 (SCN1A) Na+ channel, J Neurosci, 28, 7273, 10.1523/JNEUROSCI.4453-07.2008 · DOI
  10. Cestèle, 2013, Nonfunctional NaV1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects, Proc Natl Acad Sci USA, 110, 17546, 10.1073/pnas.1309827110 · DOI
  11. Kahlig, 2008, Divergent sodium channel defects in familial hemiplegic migraine, Proc Natl Acad Sci USA, 105, 9799, 10.1073/pnas.0711717105 · DOI
  12. Barbieri, 2019, Late sodium current blocker GS967 inhibits persistent currents induced by familial hemiplegic migraine type 3 mutations of the SCN1A gene, J Headache Pain, 20, 107, 10.1186/s10194-019-1056-2 · DOI
  13. Berkovic, 2004, Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy, Ann Neurol, 55, 550, 10.1002/ana.20029 · DOI
  14. Shi, 2012, Clinical spectrum of SCN2A mutations, Brain Dev, 34, 541, 10.1016/j.braindev.2011.09.016 · DOI
  15. Bennett, 1995, Molecular mechanism for an inherited cardiac arrhythmia, Nature, 376, 683, 10.1038/376683a0 · DOI
  16. Fonseca, 2018, Cardiac channelopathies: The role of sodium channel mutations, Rev Port Cardiol, 37, 179, 10.1016/j.repc.2017.11.007 · DOI
  17. Jurkat-Rott, 2010, Sodium channelopathies of skeletal muscle result from gain or loss of function, Pflugers Arch, 460, 239, 10.1007/s00424-010-0814-4 · DOI
  18. Lee, 2009, Clinical diversity of SCN4A-mutation-associated skeletal muscle sodium channelopathy, J Clin Neurol, 5, 186, 10.3988/jcn.2009.5.4.186 · DOI
  19. Waxman, 2013, Painful Na-channelopathies: an expanding universe, Trends Mol Med, 19, 406, 10.1016/j.molmed.2013.04.003 · DOI
  20. Faber, 2012, Gain-of-function Nav1.8 mutations in painful neuropathy, Proc Natl Acad Sci USA, 109, 19444, 10.1073/pnas.1216080109 · DOI
  21. Huang, 2014, Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy, Brain, 137, 1627, 10.1093/brain/awu079 · DOI
  22. Elia, 2019, Myasthenic congenital myopathy from recessive mutations at a single residue in Na(V)1.4, Neurology, 92, e1405, 10.1212/WNL.0000000000007185 · DOI
  23. Habbout, 2016, A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis, Neurology, 86, 161, 10.1212/WNL.0000000000002264 · DOI
  24. Wolff, 2017, Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders, Brain, 140, 1316, 10.1093/brain/awx054 · DOI · Paper page
  25. Møller, 2016, Precision medicine: SCN8A encephalopathy treated with sodium channel blockers, Neurotherapeutics, 13, 190, 10.1007/s13311-015-0403-5 · DOI
  26. Brunklaus, 2012, Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome, Brain, 135, 2329, 10.1093/brain/aws151 · DOI · Paper page
  27. Guerrini, 1998, Lamotrigine and seizure aggravation in severe myoclonic epilepsy, Epilepsia, 39, 508, 10.1111/j.1528-1157.1998.tb01413.x · DOI · Paper page
  28. Mazzanti, 2016, Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3, J Am Coll Cardiol, 67, 1053, 10.1016/j.jacc.2015.12.033 · DOI
  29. Kambouris, 2000, A revised view of cardiac sodium channel “blockade” in the long-QT syndrome, J Clin Invest, 105, 1133, 10.1172/JCI9212 · DOI
  30. Priori, 2013, HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013, Heart Rhythm, 10, 1932, 10.1016/j.hrthm.2013.05.014 · DOI · Paper page
  31. Brunklaus, 2020, SCN1A variants from bench to bedside-improved clinical prediction from functional characterization, Hum Mutat, 41, 363, 10.1002/humu.23943 · DOI
  32. Pérez-Palma, 2020, Identification of pathogenic variant enriched regions across genes and gene families, Genome Res, 30, 62, 10.1101/gr.252601.119 · DOI
  33. Meisler, 2021, Sodium channelopathies in neurodevelopmental disorders, Nat Rev Neurosci, 22, 152, 10.1038/s41583-020-00418-4 · DOI
  34. Mantegazza, 2021, Sodium channelopathies of skeletal muscle and brain, Physiol Rev, 101, 1633, 10.1152/physrev.00025.2020 · DOI
  35. Brunklaus, 2020, Biological concepts in human sodium channel epilepsies and their relevance in clinical practice, Epilepsia, 61, 387, 10.1111/epi.16438 · DOI
  36. Rhodes, 2004, Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy, Proc Natl Acad Sci USA, 101, 11147, 10.1073/pnas.0402482101 · DOI
  37. Thompson, 2012, Nontruncating SCN1A mutations associated with severe myoclonic epilepsy of infancy impair cell surface expression, J Biol Chem, 287, 42001, 10.1074/jbc.M112.421883 · DOI
  38. Fleischhauer, 1998, Effects of temperature and mexiletine on the F1473S Na+ channel mutation causing paramyotonia congenita, Pflugers Arch, 436, 757, 10.1007/s004240050699 · DOI
  39. Bechi, 2015, Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum, Neurobiol Dis, 75, 100, 10.1016/j.nbd.2014.12.028 · DOI
  40. Fertleman, 2006, SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes, Neuron, 52, 767, 10.1016/j.neuron.2006.10.006 · DOI
  41. Dib-Hajj, 2008, Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable, Mol Pain, 4, 37, 10.1186/1744-8069-4-37 · DOI
  42. Theile, 2011, Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents, J Physiol, 589, 597, 10.1113/jphysiol.2010.200915 · DOI
  43. Winkel, 2015, The role of the sodium current complex in a nonreferred nationwide cohort of sudden infant death syndrome, Heart Rhythm, 12, 1241, 10.1016/j.hrthm.2015.03.013 · DOI
  44. Abdelsayed, 2017, Differential calcium sensitivity in NaV 1.5 mixed syndrome mutants, J Physiol, 595, 6165, 10.1113/JP274536 · DOI
  45. Rusconi, 2007, Modulatory proteins can rescue a trafficking defective epileptogenic Nav1.1 Na+ channel mutant, J Neurosci, 27, 11037, 10.1523/JNEUROSCI.3515-07.2007 · DOI
  46. Catterall, 2014, Structure and function of voltage-gated sodium channels at atomic resolution, Exp Physiol, 99, 35, 10.1113/expphysiol.2013.071969 · DOI
  47. Zuberi, 2011, Genotype-phenotype associations in SCN1A-related epilepsies, Neurology, 76, 594, 10.1212/WNL.0b013e31820c309b · DOI
  48. Tarradas, 2013, A novel missense mutation, I890T, in the pore region of cardiac sodium channel causes Brugada syndrome, PLoS One, 8, e53220, 10.1371/journal.pone.0053220 · DOI
  49. Valdivia, 2002, A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine, Cardiovasc Res, 55, 279, 10.1016/S0008-6363(02)00445-5 · DOI
  50. Bechi, 2015, Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum, Neurobiol Dis, 75, 100, 10.1016/j.nbd.2014.12.028 · DOI
  51. Dhifallah, 2018, Gain of function for the SCN1A/hNav1.1-L1670W mutation responsible for familial hemiplegic migraine, Front Mol Neurosci, 11, 232, 10.3389/fnmol.2018.00232 · DOI
  52. Horga, 2013, Prevalence study of genetically defined skeletal muscle channelopathies in England, Neurology, 80, 1472, 10.1212/WNL.0b013e31828cf8d0 · DOI
  53. Loussouarn, 2015, Physiological and pathophysiological insights of Nav1.4 and Nav1.5 comparison, Front Pharmacol, 6, 314
  54. Antzelevitch, 2005, Brugada syndrome: report of the second consensus conference, Heart Rhythm, 2, 429, 10.1016/j.hrthm.2005.01.005 · DOI · Paper page
  55. Ku, 2013, A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease, Mol Psychiatry, 18, 141, 10.1038/mp.2012.58 · DOI
  56. Holland, 2018, Location: A surrogate for personalized treatment of sodium channelopathies, Ann Neurol, 84, 1, 10.1002/ana.25268 · DOI
  57. Yoshinaga, 2015, Phenotypic variability in childhood of skeletal muscle sodium channelopathies, Pediatr Neurol, 52, 504, 10.1016/j.pediatrneurol.2015.01.014 · DOI
  58. Cooper, 2005, Distribution and intensity of constraint in mammalian genomic sequence, Genome Res, 15, 901, 10.1101/gr.3577405 · DOI · Paper page
  59. Balestrini, 2021, Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies, J Neurol Neurosurg Psychiatry, 92, 1044, 10.1136/jnnp-2020-325932 · DOI · Paper page
  60. National Research Council., 2011, Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease, 142
  61. Gardella, 2019, Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes, Epilepsia, 60, S77
  62. Suetterlin, 2015, Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies, JAMA Neurol, 72, 1531, 10.1001/jamaneurol.2015.2338 · DOI
  63. Mann, 2012, R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy, J Am Coll Cardiol, 60, 1566, 10.1016/j.jacc.2012.05.050 · DOI
  64. Sadleir, 2017, Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype, Neurology, 89, 1035, 10.1212/WNL.0000000000004331 · DOI · Paper page
  65. Berecki, 2019, SCN1A gain of function in early infantile encephalopathy, Ann Neurol, 85, 514, 10.1002/ana.25438 · DOI
  66. Anderson, 2014, Antiepileptic activity of preferential inhibitors of persistent sodium current, Epilepsia, 55, 1274, 10.1111/epi.12657 · DOI
  67. Männikkö, 2018, Spider toxin inhibits gating pore currents underlying periodic paralysis, Proc Natl Acad Sci USA, 115, 4495, 10.1073/pnas.1720185115 · DOI
  68. Weuring, 2020, NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome, PLoS One, 15, 10.1371/journal.pone.0219106 · DOI
  69. Xu, 2019, Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin, Cell, 176, 702, 10.1016/j.cell.2018.12.018 · DOI
  70. Castañeda, 2018, A novel ATP1A2 mutation in a patient with hypokalaemic periodic paralysis and CNS symptoms, Brain, 141, 3308, 10.1093/brain/awy283 · DOI
  71. Xu, 2019, Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin, Cell, 176, 702, 10.1016/j.cell.2018.12.018 · DOI
  72. Mason, 2019, Resurgent and gating pore currents induced by De Novo SCN2A epilepsy mutations, eNeuro, 6, 10.1523/ENEURO.0141-19.2019 · DOI
  73. Dunlop, 2008, High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology, Nat Rev Drug Discov, 7, 358, 10.1038/nrd2552 · DOI

Cited by

See all 114

Metadata

Authors
Brunklaus, A., Feng, T., Brünger, T., Perez-Palma, E., Heyne, H., Matthews, E., Semsarian, C., Symonds, J. D., Zuberi, S. M., Lal, D., & Schorge, S.
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2022-01-17
Volume
145
Issue
12
Pages
4275-4286
ISSN
  • 0006-8950
  • 1460-2156
DOI
10.1093/brain/awac006
PMC
PMC9897196
Cited by
114
References
9
Language
en
Licence
creativecommons.org/licenses/by-nc/4.0/ (vor)
Funders
  • Dravet Syndrome Foundation (272016)
  • Agencia Nacional de Investigación y Desarrollo (PAI77200124)
  • FamilieSCN2A foundation 2020 Action Potential Grant
  • Dravet syndrome UK (16GLW00)
  • National Health and Medical Research Council (#1154992)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene variant effects across sodium channelopathies predict function and guide precision therapy. https://app.cochat.ai/papers/10.1093/brain/awac006
The paper
Brunklaus, A., Feng, T., Brünger, T., Perez-Palma, E., Heyne, H., Matthews, E., Semsarian, C., Symonds, J. D., Zuberi, S. M., Lal, D., & Schorge, S. (2022). Gene variant effects across sodium channelopathies predict function and guide precision therapy. Brain. https://doi.org/10.1093/brain/awac006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.